Sarilumab Clinical Trials
9 recruitingDrug
Phase 26Phase 33Phase 12Phase 41
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled5 locationsNCT07154290
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled52 locationsNCT06787612
Recruiting
Phase 4
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Polymyalgia Rheumatica
Sanofi300 enrolled5 locationsNCT07286214
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 2
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
MelanomaUnresectable Melanoma
NYU Langone Health105 enrolled4 locationsNCT05428007
Recruiting
Phase 1Phase 2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Regeneron Pharmaceuticals612 enrolled24 locationsNCT04590326
Recruiting
Phase 2Phase 3
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Skin InflammationAllergic Contact Dermatitis
Wei-Che Ko45 enrolled1 locationNCT05535738
Recruiting
Phase 3
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Rheumatoid Arthritis
University of Nebraska400 enrolled1 locationNCT03414502
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707